Calbindin 2 as a Novel Biomarker and Therapeutic Target for Abdominal Aortic Aneurysm: Integrative Analysis of Human Proteomes and Genetics

Background Abdominal aortic aneurysm (AAA) is a clinical life‐threatening issue. No pharmacological treatments are currently approved for the prevention and treatment of AAA. Therefore, identifying novel biomarkers and therapeutic targets is crucial for improving AAA management and outcomes. Methods...

Full description

Saved in:
Bibliographic Details
Main Authors: Yulin Bao, Jiayi Chen, Xudong Han, Ye He, Tongtong Yang, Xinying Shi, Jiawen Chen, Lingfeng Gu, Sibo Wang, Liping Xie, Hao Wang, Liansheng Wang
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.124.039195
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849736520557133824
author Yulin Bao
Jiayi Chen
Xudong Han
Ye He
Tongtong Yang
Xinying Shi
Jiawen Chen
Lingfeng Gu
Sibo Wang
Liping Xie
Hao Wang
Liansheng Wang
author_facet Yulin Bao
Jiayi Chen
Xudong Han
Ye He
Tongtong Yang
Xinying Shi
Jiawen Chen
Lingfeng Gu
Sibo Wang
Liping Xie
Hao Wang
Liansheng Wang
author_sort Yulin Bao
collection DOAJ
description Background Abdominal aortic aneurysm (AAA) is a clinical life‐threatening issue. No pharmacological treatments are currently approved for the prevention and treatment of AAA. Therefore, identifying novel biomarkers and therapeutic targets is crucial for improving AAA management and outcomes. Methods To identify plasma proteins with potential causal effects on AAA, we integrated genetic evidence from proteome‐wide Mendelian randomization, genetic correlation, and colocalization analysis. The role of identified proteins in AAA was further explored through the phenome‐wide association study and mediation analysis. Multiomics data analysis, including bulk RNA sequencing, single‐cell/single‐nucleus RNA sequencing, and spatial transcriptomics, was employed to characterize the expression patterns of these proteins. Experimental validation was performed using an AAA model in apolipoprotein E‐deficient mice infused with angiotensin II. Druggability analysis was conducted to identify drug candidates, which were tested in preclinical mouse models. Results CALB2 (calbindin 2) was identified as having a causal effect on AAA and may influence the progression of AAA through the regulation of lipid metabolism. Multiomics analysis revealed that CALB2 is predominantly expressed in the mesothelial cells of adipose tissues. Inhibition of CALB2 in an AAA mouse model alleviated AAA progression. Druggability analysis identified lenalidomide and genistein as potential therapeutic candidates, and experiments confirmed their efficacy in preventing AAA development. Conclusions This study identifies CALB2 as being associated with an increased risk of AAA and suggests that i might be a novel biomarker and therapeutic molecule for AAA management. Lenalidomide and genistein hold promising potential as treatments for patients with AAA.
format Article
id doaj-art-2126a1e5d6ac495ca429fa57470c57cc
institution DOAJ
issn 2047-9980
language English
publishDate 2025-05-01
publisher Wiley
record_format Article
series Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
spelling doaj-art-2126a1e5d6ac495ca429fa57470c57cc2025-08-20T03:07:16ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802025-05-0114910.1161/JAHA.124.039195Calbindin 2 as a Novel Biomarker and Therapeutic Target for Abdominal Aortic Aneurysm: Integrative Analysis of Human Proteomes and GeneticsYulin Bao0Jiayi Chen1Xudong Han2Ye He3Tongtong Yang4Xinying Shi5Jiawen Chen6Lingfeng Gu7Sibo Wang8Liping Xie9Hao Wang10Liansheng Wang11Department of Cardiology The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu ChinaDepartment of Cardiology The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu ChinaDepartment of Cardiology The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu ChinaDepartment of Cardiology The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu ChinaDepartment of Cardiology The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu ChinaDepartment of Cardiology The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu ChinaDepartment of Cardiology The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu ChinaDepartment of Cardiology The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu ChinaDepartment of Cardiology The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu ChinaKey Laboratory of Cardiovascular and Cerebrovascular Medicine, Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine Nanjing Medical University Nanjing Jiangsu ChinaDepartment of Cardiology The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu ChinaDepartment of Cardiology The First Affiliated Hospital with Nanjing Medical University Nanjing Jiangsu ChinaBackground Abdominal aortic aneurysm (AAA) is a clinical life‐threatening issue. No pharmacological treatments are currently approved for the prevention and treatment of AAA. Therefore, identifying novel biomarkers and therapeutic targets is crucial for improving AAA management and outcomes. Methods To identify plasma proteins with potential causal effects on AAA, we integrated genetic evidence from proteome‐wide Mendelian randomization, genetic correlation, and colocalization analysis. The role of identified proteins in AAA was further explored through the phenome‐wide association study and mediation analysis. Multiomics data analysis, including bulk RNA sequencing, single‐cell/single‐nucleus RNA sequencing, and spatial transcriptomics, was employed to characterize the expression patterns of these proteins. Experimental validation was performed using an AAA model in apolipoprotein E‐deficient mice infused with angiotensin II. Druggability analysis was conducted to identify drug candidates, which were tested in preclinical mouse models. Results CALB2 (calbindin 2) was identified as having a causal effect on AAA and may influence the progression of AAA through the regulation of lipid metabolism. Multiomics analysis revealed that CALB2 is predominantly expressed in the mesothelial cells of adipose tissues. Inhibition of CALB2 in an AAA mouse model alleviated AAA progression. Druggability analysis identified lenalidomide and genistein as potential therapeutic candidates, and experiments confirmed their efficacy in preventing AAA development. Conclusions This study identifies CALB2 as being associated with an increased risk of AAA and suggests that i might be a novel biomarker and therapeutic molecule for AAA management. Lenalidomide and genistein hold promising potential as treatments for patients with AAA.https://www.ahajournals.org/doi/10.1161/JAHA.124.039195abdominal aortic aneurysmcalbindin 2Mendelian randomizationplasma proteinproteogenomic
spellingShingle Yulin Bao
Jiayi Chen
Xudong Han
Ye He
Tongtong Yang
Xinying Shi
Jiawen Chen
Lingfeng Gu
Sibo Wang
Liping Xie
Hao Wang
Liansheng Wang
Calbindin 2 as a Novel Biomarker and Therapeutic Target for Abdominal Aortic Aneurysm: Integrative Analysis of Human Proteomes and Genetics
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
abdominal aortic aneurysm
calbindin 2
Mendelian randomization
plasma protein
proteogenomic
title Calbindin 2 as a Novel Biomarker and Therapeutic Target for Abdominal Aortic Aneurysm: Integrative Analysis of Human Proteomes and Genetics
title_full Calbindin 2 as a Novel Biomarker and Therapeutic Target for Abdominal Aortic Aneurysm: Integrative Analysis of Human Proteomes and Genetics
title_fullStr Calbindin 2 as a Novel Biomarker and Therapeutic Target for Abdominal Aortic Aneurysm: Integrative Analysis of Human Proteomes and Genetics
title_full_unstemmed Calbindin 2 as a Novel Biomarker and Therapeutic Target for Abdominal Aortic Aneurysm: Integrative Analysis of Human Proteomes and Genetics
title_short Calbindin 2 as a Novel Biomarker and Therapeutic Target for Abdominal Aortic Aneurysm: Integrative Analysis of Human Proteomes and Genetics
title_sort calbindin 2 as a novel biomarker and therapeutic target for abdominal aortic aneurysm integrative analysis of human proteomes and genetics
topic abdominal aortic aneurysm
calbindin 2
Mendelian randomization
plasma protein
proteogenomic
url https://www.ahajournals.org/doi/10.1161/JAHA.124.039195
work_keys_str_mv AT yulinbao calbindin2asanovelbiomarkerandtherapeutictargetforabdominalaorticaneurysmintegrativeanalysisofhumanproteomesandgenetics
AT jiayichen calbindin2asanovelbiomarkerandtherapeutictargetforabdominalaorticaneurysmintegrativeanalysisofhumanproteomesandgenetics
AT xudonghan calbindin2asanovelbiomarkerandtherapeutictargetforabdominalaorticaneurysmintegrativeanalysisofhumanproteomesandgenetics
AT yehe calbindin2asanovelbiomarkerandtherapeutictargetforabdominalaorticaneurysmintegrativeanalysisofhumanproteomesandgenetics
AT tongtongyang calbindin2asanovelbiomarkerandtherapeutictargetforabdominalaorticaneurysmintegrativeanalysisofhumanproteomesandgenetics
AT xinyingshi calbindin2asanovelbiomarkerandtherapeutictargetforabdominalaorticaneurysmintegrativeanalysisofhumanproteomesandgenetics
AT jiawenchen calbindin2asanovelbiomarkerandtherapeutictargetforabdominalaorticaneurysmintegrativeanalysisofhumanproteomesandgenetics
AT lingfenggu calbindin2asanovelbiomarkerandtherapeutictargetforabdominalaorticaneurysmintegrativeanalysisofhumanproteomesandgenetics
AT sibowang calbindin2asanovelbiomarkerandtherapeutictargetforabdominalaorticaneurysmintegrativeanalysisofhumanproteomesandgenetics
AT lipingxie calbindin2asanovelbiomarkerandtherapeutictargetforabdominalaorticaneurysmintegrativeanalysisofhumanproteomesandgenetics
AT haowang calbindin2asanovelbiomarkerandtherapeutictargetforabdominalaorticaneurysmintegrativeanalysisofhumanproteomesandgenetics
AT lianshengwang calbindin2asanovelbiomarkerandtherapeutictargetforabdominalaorticaneurysmintegrativeanalysisofhumanproteomesandgenetics